SLNO
HealthcareSoleno Therapeutics, Inc. · Biotechnology · $3B
What is Soleno Therapeutics, Inc.?
Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Its pipeline centers on a single lead candidate targeting Prader-Willi Syndrome, a complex genetic disorder with limited approved therapies.
Soleno Therapeutics advances novel oral therapeutics through clinical development for rare, underserved conditions. Its lead program — Diazoxide Choline Controlled-Release — is a once-daily oral tablet currently in Phase III trials for Prader-Willi Syndrome. The company generates no product revenue at this stage; its value is tied to clinical outcomes and the regulatory pathway toward potential commercialization of its lead asset.
Incorporated in 1999 and rebranded as Soleno Therapeutics in 2017, the company is headquartered in Redwood City, California.
- Diazoxide Choline Controlled-Release (DCCR) — once-daily oral tablet for Prader-Willi Syndrome
- Phase III rare disease clinical development program
- Focused rare disease commercialization strategy
Is SLNO a Good Stock to Buy?
UQS Score rates SLNO as Good overall, reflecting a mixed profile typical of clinical-stage rare disease companies.
The Risk pillar stands out as the strongest element of SLNO's profile, suggesting the company's financial positioning and risk management compare favorably relative to peers at a similar development stage. The Growth pillar also registers as Good, reflecting the potential runway associated with an active Phase III program in an indication with significant unmet medical need.
Both the Quality and Moat pillars rate as Weak, which is consistent with a pre-revenue biotech that has yet to establish durable competitive advantages or a track record of earnings.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SLNO pay dividends?
No — Soleno Therapeutics, Inc. does not currently pay a dividend.
Soleno Therapeutics does not pay a dividend. As a clinical-stage company with no commercial revenue, available capital is directed toward advancing its Phase III program and supporting regulatory activities. Income-focused investors should note that dividends are unlikely until the company reaches commercialization and sustained profitability.
When does SLNO report earnings?
Soleno Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly results primarily reflect operating expenses related to research, development, and general administration rather than product sales. Investors typically focus on pipeline milestones, cash runway, and trial updates rather than traditional revenue metrics.
For the most recent quarter's results and management commentary, visit Soleno Therapeutics' investor relations page directly.
SLNO Price History
-31.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Soleno Therapeutics, Inc.?
Based on Soleno Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SLNO Long-term Outlook
The fundamental outlook for SLNO is shaped by its Phase III clinical program. A Good Growth pillar rating indicates meaningful upside potential if the lead asset progresses toward regulatory submission. The Strong Risk rating suggests the company is relatively well-positioned to manage near-term financial pressures. However, the Weak Quality and Moat ratings reflect the inherent uncertainty of pre-commercial biotechs — outcomes remain binary and dependent on clinical and regulatory events.
Growth drivers
- Phase III trial progression and potential regulatory approval for DCCR in Prader-Willi Syndrome
- Rare disease designation benefits, including expedited review pathways and market exclusivity
- Significant unmet medical need in Prader-Willi Syndrome with limited existing treatment options
Key risks
- Clinical trial failure or unexpected safety findings could materially impair the company's value
- Pre-revenue status means continued reliance on capital markets to fund operations
- Neutral Valuation pillar suggests the market has already priced in meaningful clinical optimism
SLNO vs Peers
Soleno Therapeutics operates in the rare disease and specialty biopharmaceutical space alongside several focused peers.
Disc Medicine targets hematologic rare diseases, pursuing a distinct therapeutic area from Soleno's metabolic and neurological focus in Prader-Willi Syndrome.
Veracyte focuses on genomic diagnostics for cancer, representing a commercial-stage rare disease adjacent company with a different revenue model than Soleno's clinical-stage pipeline.
Zai Lab is a commercial-stage biopharma with a broader oncology and rare disease portfolio, offering a more diversified pipeline compared to Soleno's single-asset focus.
Frequently Asked Questions
What does Soleno Therapeutics do?
Soleno Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare diseases. Its primary focus is Diazoxide Choline Controlled-Release, a once-daily oral tablet in Phase III trials for Prader-Willi Syndrome — a rare genetic disorder with few approved treatment options.
Does SLNO pay dividends?
No, Soleno Therapeutics does not currently pay a dividend. The company is pre-revenue and directs its capital toward clinical development. Dividends are not expected until the company achieves commercial-stage profitability.
When does SLNO report earnings?
Soleno Therapeutics reports on a quarterly basis, as is standard for US-listed companies. For exact dates and the most recent results, check the investor relations section of the company's official website.
Is SLNO a good stock to buy?
UQS Score rates SLNO as Good overall. The Growth and Risk pillars are relative strengths, while Quality and Moat are rated Weak — consistent with a pre-revenue clinical-stage company. Whether it fits your portfolio depends on your risk tolerance and investment horizon. View the full breakdown on UQS Score.
Is SLNO overvalued?
The UQS Valuation pillar for SLNO is rated Neutral, suggesting the market's current pricing is neither clearly attractive nor elevated relative to the company's stage and prospects. Full valuation metrics are available to Pro members on UQS Score.
How does SLNO compare to its competitors?
Compared to peers like Disc Medicine, Veracyte, and Zai Lab, Soleno is more narrowly focused — its entire pipeline centers on a single rare disease indication. This concentration creates higher binary risk but also a clearer value catalyst if its Phase III program succeeds.
What is SLNO's market cap bracket?
Soleno Therapeutics is classified as a mid-cap company. For a clinical-stage rare disease biotech, this reflects meaningful investor interest in the potential of its lead Phase III program.
Who founded Soleno Therapeutics?
The company was originally incorporated in 1999 under the name Capnia, Inc. and rebranded as Soleno Therapeutics in May 2017. Detailed founding history is publicly available through SEC filings and the company's official investor relations materials.
Is SLNO a long-term quality investment?
From a long-term quality perspective, SLNO's Weak Quality and Moat ratings reflect the challenges of pre-commercial biotech investing. The Strong Risk and Good Growth ratings indicate near-term resilience and upside potential, but long-term quality will depend heavily on clinical and commercial execution. Pro members can view the full pillar analysis on UQS Score.
What is the main competitive advantage of Soleno Therapeutics?
Soleno's primary advantage lies in its focus on Prader-Willi Syndrome, a rare condition with significant unmet need and limited competition. Rare disease programs often benefit from regulatory incentives such as orphan drug designation, which can provide market exclusivity and expedited review pathways.
What sector does SLNO belong to?
Soleno Therapeutics operates in the Healthcare sector, specifically within clinical-stage rare disease biopharmaceuticals. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) on the platform.
Is SLNO a growth stock or value stock?
Based on its UQS pillar profile, SLNO leans toward the growth category — its Growth pillar is rated Good, reflecting pipeline-driven upside potential. The Neutral Valuation rating suggests the market has already incorporated some of that optimism into the current price.
Unlock Full SLNO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics and quality indicators
- ✓Compare SLNO against rare disease peers side by side
- ✓Track Growth and Risk pillar changes over time
- ✓Get the complete analyst-style breakdown in one place
Pro Analysis
SLNO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 64.7 | 80.5 | 35.0 | 61.2 | 100.0 | 57.4 | +13.5 |
| May 7, 2026 | 51.2 | 36.2 | 35.0 | 61.2 | 83.5 | 57.4 | 0.0 |
| Apr 22, 2026 | 51.2 | 36.2 | 35.0 | 61.2 | 83.5 | 57.7 | -3.1 |
| Apr 18, 2026 | 54.3 | 36.2 | 35.0 | 76.5 | 83.5 | 57.8 | -2.1 |
| Apr 12, 2026 | 56.4 | 36.2 | 35.0 | 76.5 | 83.5 | 72.2 | -1.2 |
| Apr 5, 2026 | 57.6 | 36.2 | 35.0 | 76.5 | 83.5 | 79.7 | -0.3 |
| Apr 2, 2026 | 57.9 | 36.2 | 35.0 | 76.5 | 83.5 | 81.8 | — |
SLNO — Pillar Breakdown
Quality
— 80.5/100 (25%)Soleno Therapeutics, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 61.2/100 (20%)Soleno Therapeutics, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 100.0/100 (15%)Soleno Therapeutics, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 57.4/100 (15%)Soleno Therapeutics, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 35/100 (25%)Soleno Therapeutics, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SLNO.
Score Composition
Financial Data
More Stock Analysis
How is the SLNO UQS Score Calculated?
The UQS (Unified Quality Score) for Soleno Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Soleno Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Soleno Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.